Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VRC CHKVLP059 00 VP

Next Previous
Drug Profile

VRC CHKVLP059 00 VP

Alternative Names: Alum-adjuvanted chikungunya virus-like particle vaccine; Chikungunya virus virus-like particle vaccine; Chikungunya-virus-vaccine-VRC; CHIKV-VLP; PXVX 0317; VIMKUNYA; VRC-CHKVLP059-00-VP

Latest Information Update: 26 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Developer Bavarian Nordic; Emergent BioSolutions; National Institute of Allergy and Infectious Diseases
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chikungunya virus infections

Most Recent Events

  • 16 Apr 2026 Registered for Chikungunya virus infections (Prevention, In children, In adolescents, In adults) in Switzerland (IM)
  • 12 Mar 2026 Bavarian Nordic plans a phase IIIb trial for Chikungunya virus infections (Prevention, In adolescents, In adults) in Philippines, Thailand(IM) in May 2026 (NCT07467707)
  • 23 Jan 2026 Bavarian Nordic announces intention to submit BLA to Brazilian Health Regulatory Agency Anvisa for Chikungunya virus infections in the first half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top